{"id":1022,"date":"2025-12-12T00:51:42","date_gmt":"2025-12-12T00:51:42","guid":{"rendered":"https:\/\/test.geo-tester.com\/?p=1022"},"modified":"2025-12-12T00:52:10","modified_gmt":"2025-12-12T00:52:10","slug":"10-essential-benefits-of-a-reliable-softgel-capsule-hardness-tester","status":"publish","type":"post","link":"https:\/\/test.geo-tester.com\/hu\/resources\/10-essential-benefits-of-a-reliable-softgel-capsule-hardness-tester.html","title":{"rendered":"10 alapvet\u0151 el\u0151nyei egy megb\u00edzhat\u00f3 l\u00e1gykapszula kapszula kem\u00e9nys\u00e9gm\u00e9r\u0151nek"},"content":{"rendered":"

Mi az a l\u00e1gyg\u00e9l kapszula kem\u00e9nys\u00e9ge<\/a> tesztel\u0151? A l\u00e1gyzselatin kapszul\u00e1kat csomagol\u00e1s el\u0151tt rugalmass\u00e1gi vizsg\u00e1latnak kell al\u00e1vetni. Itt van sz\u00fcks\u00e9g a tesztel\u0151re, \u00e9s nem egy k\u00f6z\u00f6ns\u00e9ges tesztel\u0151re.<\/p>\n\n\n\n

A kapszul\u00e1k gy\u00e1rt\u00f3inak megb\u00edzhat\u00f3 l\u00e1gyzsel\u00e9s kapszula kem\u00e9nys\u00e9gtesztre van sz\u00fcks\u00e9g\u00fck annak biztos\u00edt\u00e1s\u00e1ra, hogy term\u00e9keik megfeleljenek a meghat\u00e1rozott ipari szabv\u00e1nymin\u0151s\u00e9gnek, miel\u0151tt a term\u00e9keket a fogyaszt\u00f3k\u00f6z\u00f6ns\u00e9gnek kiadj\u00e1k.<\/p>\n\n\n\n

Az eredm\u00e9ny megmutatja, hogy a kapszula rendelkezik-e a csomagol\u00e1shoz sz\u00fcks\u00e9ges ind\u00edt\u00f3jelz\u00e9ssel vagy sem. \u00cdgy megel\u0151zhet\u0151 a csomagol\u00e1s sor\u00e1n bek\u00f6vetkez\u0151 ism\u00e9telt meghib\u00e1sod\u00e1s, ami a gy\u00e1rt\u00f3 sz\u00e1m\u00e1ra t\u00f6bbletk\u00f6lts\u00e9geket jelenthet.<\/p>\n\n\n\n

A Gelomat c\u00e9lja, hogy a zselatinkapszul\u00e1k tesztel\u00e9se sor\u00e1n a legmagasabb min\u0151s\u00e9gi szabv\u00e1nyokat \u00e9rje el.<\/p>\n\n\n\n

T\u00f6bb inform\u00e1ci\u00f3 a Soft Gel kapszul\u00e1kr\u00f3l<\/h2>\n\n\n\n

Vannak szab\u00e1lyok az agelatin kem\u00e9nys\u00e9gteszterin kapszul\u00e1s term\u00e9kek haszn\u00e1lat\u00e1ra vonatkoz\u00f3an. Jellemz\u0151en a sz\u00fcks\u00e9ges tesztek sz\u00e1ma a kapszula egys\u00e9gd\u00f3zis\u00e1t\u00f3l f\u00fcgg. Azonban sz\u00e1mos egy\u00e9b el\u0151nyt k\u00edn\u00e1l, amelyeket ez a cikk megvizsg\u00e1l.<\/p>\n\n\n\n

De el\u0151bb elmondjuk, mit kell tudnia a l\u00e1gyzsel\u00e9s kapszul\u00e1kr\u00f3l. Ezeket a term\u00e9keket t\u00falnyom\u00f3r\u00e9szt gy\u00f3gyszerek, \u00e1sv\u00e1nyi anyagokat tartalmaz\u00f3 \u00e9trend-kieg\u00e9sz\u00edt\u0151k \u00e9s vitaminok eset\u00e9ben haszn\u00e1lj\u00e1k. A kapszul\u00e1k vagy mikrokapszul\u00e1k belsej\u00e9be hat\u00f3anyagokat csomagolnak, hogy megv\u00e9dj\u00e9k a term\u00e9ket a k\u00fcl\u00f6nb\u00f6z\u0151 t\u00e9nyez\u0151kt\u0151l.<\/p>\n\n\n\n

Ezek a hat\u00f3anyagok diff\u00fazi\u00f3, olvad\u00e1s, felold\u00f3d\u00e1s vagy felszakad\u00e1s \u00fatj\u00e1n szabadulnak fel, amint a szem\u00e9ly a kapszul\u00e1t a sz\u00e1j\u00e1ba veszi. Az, hogy a hat\u00f3anyagok milyen lassan vagy gyorsan szabadulnak fel, a kapszula fal\u00e1nak szil\u00e1rds\u00e1g\u00e1t\u00f3l f\u00fcgg.<\/p>\n\n\n\n

A l\u00e1gy g\u00e9lkapszul\u00e1k, m\u00e1s n\u00e9ven g\u00e9lkapszul\u00e1k vagy zselatin kapszul\u00e1k, \u00e1llati csont \u00e9s b\u0151r kollag\u00e9nb\u0151l k\u00e9sz\u00fclnek, amelyet zselatin el\u0151\u00e1ll\u00edt\u00e1s\u00e1hoz gy\u00e1rtanak. Vannak cellul\u00f3zb\u00f3l k\u00e9sz\u00fclt n\u00f6v\u00e9nyi vagy veget\u00e1ri\u00e1nus kapszul\u00e1k is, amelyek f\u0151 \u00f6sszetev\u0151je a HPMC vagy hidroxipropil-metilcellul\u00f3z. A g\u00e9lkapszul\u00e1k el\u0151\u00e1ll\u00edt\u00e1sa azonban k\u00f6lts\u00e9ghat\u00e9konyabb, ez\u00e9rt sz\u00e9lesebb k\u00f6rben haszn\u00e1lj\u00e1k, mint a m\u00e1sik t\u00edpust.<\/p>\n\n\n\n

K\u00e9tf\u00e9le zselatinkapszula l\u00e9tezik - l\u00e1gy \u00e9s kem\u00e9ny h\u00e9j\u00fa.<\/p>\n\n\n\n

L\u00e1gy h\u00e9j\u00fa kapszul\u00e1k<\/strong> olajokat tartalmaznak, vagy olajban szuszpend\u00e1lt vagy feloldott hat\u00f3anyagokat haszn\u00e1lnak.<\/p>\n\n\n\n

Kem\u00e9ny h\u00e9j\u00fa kapszul\u00e1k<\/strong> miniat\u0171r pellet vagy sz\u00e1raz, por\u00edtott \u00f6sszetev\u0151k. K\u00e9t r\u00e9szb\u0151l k\u00e9sz\u00fclnek: Az egyik fele tartalmazza a gy\u00f3gyszert, a m\u00e1sik fele pedig nagyobb \u00e1tm\u00e9r\u0151j\u0171, \u00e9s kupakk\u00e9nt szolg\u00e1l a kapszula lez\u00e1r\u00e1s\u00e1ra.<\/p>\n\n\n\n

Minden a Gelomat kapszul\u00e1r\u00f3l Kem\u00e9nys\u00e9gm\u00e9r\u0151<\/a><\/h2>\n\n\n\n

A Gelomat egy olyan eszk\u00f6z, amelyet a kapszula kem\u00e9nys\u00e9g\u00e9nek automatikus vizsg\u00e1lat\u00e1ra haszn\u00e1lnak. L\u00e1gy kapszul\u00e1k \u00e9s norm\u00e1l kapszul\u00e1k eset\u00e9ben egyar\u00e1nt m\u0171k\u00f6dik. K\u00e9pes az \u00e9tkez\u00e9si zselatin, plasztilin, zselatin kapszul\u00e1k \u00e9s m\u00e1s anyagok kem\u00e9nys\u00e9gvizsg\u00e1lat\u00e1nak elv\u00e9gz\u00e9s\u00e9re. A k\u00e9sz\u00fcl\u00e9k alapfelszerelts\u00e9g\u0171 tesztel\u0151fejjel \u00e9rkezik, de egy\u00e9b tartoz\u00e9kokkal b\u0151v\u00edthet\u0151 a k\u00e9sz\u00fcl\u00e9k \u00e9s n\u00f6velhet\u0151 a hat\u00e9konys\u00e1ga.<\/p>\n\n\n\n

A Gelomat c\u00e9lja, hogy a zselatinkapszul\u00e1k tesztel\u00e9se sor\u00e1n a legmagasabb min\u0151s\u00e9gi szabv\u00e1nyokat \u00e9rje el. A leg\u00fajabb K+F technol\u00f3gia \u00e9s egy korszer\u0171 rendszer felhaszn\u00e1l\u00e1s\u00e1val fejlesztett\u00e9k ki. A k\u00e9sz\u00fcl\u00e9k felszerelhet\u0151 k\u00fcl\u00f6nb\u00f6z\u0151 terhelhet\u0151s\u00e9g\u0171 vizsg\u00e1l\u00f3fejekkel: 0-2N \u00e9s 0-20N. A kezel\u0151 v\u00e1laszthat a fejek k\u00f6z\u00fcl, \u00e9s az ig\u00e9nyeknek megfelel\u0151en cser\u00e9lheti \u0151ket.<\/p>\n\n\n\n

A megb\u00edzhat\u00f3 l\u00e1gykapszula-kem\u00e9nys\u00e9gm\u00e9r\u0151 legf\u0151bb el\u0151nyei<\/h2>\n\n\n\n

1. Rombol\u00e1smentes megold\u00e1s<\/strong><\/h3>\n\n\n\n

A Gelomat roncsol\u00e1smentes megold\u00e1st k\u00edn\u00e1l a l\u00e1gyzsel\u00e9s kapszul\u00e1k kem\u00e9nys\u00e9g\u00e9nek vizsg\u00e1lat\u00e1ra. A l\u00e1gy g\u00e9lkapszul\u00e1kon \u00e9s zselatinon k\u00edv\u00fcl agarok, paintball, j\u00e1t\u00e9kt\u00e9szta \u00e9s egy\u00e9b anyagok ellen\u00e1ll\u00e1s\u00e1t \u00e9s kem\u00e9nys\u00e9g\u00e9t is k\u00e9pes m\u00e9rni. A digit\u00e1lis m\u00e9r\u0151rendszerek \u00e9s a k\u00e9sz\u00fcl\u00e9k egyedi kialak\u00edt\u00e1sa biztos\u00edtja a legmegb\u00edzhat\u00f3bb \u00e9s legmagasabb szint\u0171 m\u00e9r\u00e9si pontoss\u00e1got.<\/p>\n\n\n\n

A szabv\u00e1nyos 0-2N vagy 0-20N m\u00e9r\u0151fej haszn\u00e1lat\u00e1n k\u00edv\u00fcl a kezel\u0151 v\u00e1laszthatja a Centrofix vagy Rotofix r\u00f6gz\u00edt\u00e9s\u00e9t is. A Centrofix egy k\u00e9zzel m\u0171k\u00f6dtetett mintatart\u00f3 r\u00f6gz\u00edt\u0151elem. A Rotofix egy automatikusan m\u0171k\u00f6d\u0151 pozicion\u00e1l\u00f3 eszk\u00f6z. A felhaszn\u00e1l\u00f3 a szoftver seg\u00edts\u00e9g\u00e9vel olyan funkci\u00f3kat v\u00e9gezhet, mint p\u00e9ld\u00e1ul k\u00f6tegelt mapp\u00e1k l\u00e9trehoz\u00e1sa, hisztogramok megtekint\u00e9se, adatok t\u00e1rol\u00e1sa, az eredm\u00e9nyek elemz\u00e9se stb.<\/p>\n\n\n\n

Mi\u00e9rt ez a nagy felhajt\u00e1s a l\u00e1gyzsel\u00e9s kapszul\u00e1k tesztel\u00e9se k\u00f6r\u00fcl? A kapszul\u00e1z\u00e1si folyamat apr\u00f3l\u00e9kos, de a form\u00e1ra \u00f6sszpontos\u00edt. Biztos\u00edtja, hogy a kapszula kialakuljon \u00e9s meg tudja tartani a t\u00f6ltel\u00e9ket. Miut\u00e1n a kapszul\u00e1k minden sz\u00fcks\u00e9ges l\u00e9p\u00e9sen \u00e1tmentek a v\u00e9gs\u0151 form\u00e1juk el\u00e9r\u00e9s\u00e9hez, k\u00f6vetkezik a tesztel\u00e9s.<\/p>\n\n\n\n

Itt megn\u00e9zz\u00fck a l\u00e1gy g\u00e9lkapszul\u00e1k k\u00e9sz\u00edt\u00e9s\u00e9nek l\u00e9p\u00e9seit:<\/p>\n\n\n\n

Egy 24 h\u00fcvelyk \u00e1tm\u00e9r\u0151j\u0171 rozsdamentes ac\u00e9l dob lassan forog, mik\u00f6zben a meleg foly\u00e9kony zselatint ki\u00f6ntik.<\/p>\n\n\n\n

A dobot a kompresszor percenk\u00e9nti 400 k\u00f6bl\u00e1bnyi \u00e1raml\u00e1si sebess\u00e9g\u00e9nek teszik ki, a leveg\u0151 h\u0151m\u00e9rs\u00e9klete 590 F-ig terjed, 20 sz\u00e1zal\u00e9kos relat\u00edv p\u00e1ratartalom mellett.<\/p>\n\n\n\n

Ahogy a dob tov\u00e1bb forog, a zselatin a h\u0171v\u00f6s, sz\u00e1raz leveg\u0151vel megdermed, am\u00edg a m\u00e1sik v\u00e9g\u00e9n egy rugalmas \u00e9s ragad\u00f3s szalag g\u00f6rd\u00fcl.<\/p>\n\n\n\n

A v\u00e9kony s\u00e1v alkotja a kapszul\u00e1kat. A folyamat automatikusan t\u00f6rt\u00e9nik.<\/p>\n\n\n\n

A kapszul\u00e1k a gy\u00e1rt\u00f3 term\u00e9keivel vannak t\u00f6ltve, p\u00e9ld\u00e1ul vitaminokkal, gy\u00f3gyszerekkel, \u00e9trend-kieg\u00e9sz\u00edt\u0151kkel \u00e9s egyebekkel.<\/p>\n\n\n\n

A megt\u00f6lt\u00f6tt kapszul\u00e1kat lez\u00e1rj\u00e1k \u00e9s egy t\u00e1lc\u00e1ba dobj\u00e1k.<\/p>\n\n\n\n

A megt\u00f6lt\u00f6tt kapszul\u00e1k m\u00e9g nedvesek \u00e9s puh\u00e1k, ez\u00e9rt kamr\u00e1kba vagy sz\u00e1r\u00edt\u00f3dobokba ker\u00fclnek.<\/p>\n\n\n\n

A sz\u00e1r\u00edt\u00e1si id\u0151 sz\u00e1mos t\u00e9nyez\u0151t\u0151l f\u00fcgg, t\u00f6bbek k\u00f6z\u00f6tt a nedvess\u00e9g elt\u00e1vol\u00edt\u00e1s\u00e1hoz sz\u00fcks\u00e9ges id\u0151t\u0151l, a kapszul\u00e1k sz\u00e1m\u00e1t\u00f3l \u00e9s a kapszul\u00e1k m\u00e9ret\u00e9t\u0151l.<\/p>\n\n\n\n

Ennyire apr\u00f3l\u00e9kos a l\u00e1gy g\u00e9lkapszul\u00e1k kialak\u00edt\u00e1sa. A leveg\u0151 h\u0151m\u00e9rs\u00e9klete, amelynek a dob az \u00f6nt\u00e9si folyamat sor\u00e1n ki van t\u00e9ve, d\u00f6nt\u0151 fontoss\u00e1g\u00fa, mivel ez okozhatja a g\u00e9lek t\u00fals\u00e1gosan t\u00f6r\u00e9kenny\u00e9 v\u00e1l\u00e1s\u00e1t vagy t\u00fal gyors szil\u00e1rdul\u00e1s\u00e1t. Mindk\u00e9t eredm\u00e9ny le\u00e1ll\u00edthatja a gy\u00e1rt\u00e1st, \u00e9s a folyamatot el\u00f6lr\u0151l kell megism\u00e9telni.<\/p>\n\n\n\n

Ha a leveg\u0151 sebess\u00e9ge t\u00fal nagy, a g\u00e9lkapszul\u00e1k vastags\u00e1ga vagy v\u00e9konys\u00e1ga nem lesz egyenletes. M\u00e1sr\u00e9szt, ha t\u00fal alacsony, \u00e9s a p\u00e1ratartalom \u00e9s a leveg\u0151 h\u0151m\u00e9rs\u00e9klete t\u00fal magas, a zselatin nehezen fog megszil\u00e1rdulni.<\/p>\n\n\n\n

A sz\u00e1r\u00edt\u00e1si id\u0151 alatt folyamatosan szab\u00e1lyozni kell a k\u00f6rnyezet h\u0151m\u00e9rs\u00e9klet\u00e9t. Az ide\u00e1lis p\u00e1ratartalom 20 szem\/kilogramm leveg\u0151 \u00e9s 25\u00b0 F harmatpont.<\/p>\n\n\n\n

Amikor a kapszul\u00e1k teljesen megsz\u00e1radtak, egy l\u00e1gykapszula kem\u00e9nys\u00e9gm\u00e9r\u0151vel, p\u00e9ld\u00e1ul a Gelomat seg\u00edts\u00e9g\u00e9vel tesztelj\u00fck \u0151ket. M\u00e9g ekkor is a vizsg\u00e1lati eredm\u00e9nyekt\u0151l f\u00fcgg, hogy v\u00e9g\u00fcl h\u00e1ny kapszula ker\u00fcl forgalomba. Ez biztos\u00edtja, hogy a tart\u00f3s\u00edtott k\u00e9szlet \u00e9rt\u00e9ket k\u00e9pviseljen, \u00e9s ne vesz\u00e9lyeztesse a gy\u00e1rt\u00f3 nev\u00e9t.<\/p>\n\n\n\n

Mi\u00e9rt fontos, hogy az eszk\u00f6z nagym\u00e9rt\u00e9kben reproduk\u00e1lhat\u00f3 legyen? A kapszul\u00e1kat t\u00e9telekben tesztelik, \u00e9s a t\u00e9telben mindegyiknek a t\u00f6bbihez hasonl\u00f3 tulajdons\u00e1gokkal \u00e9s kem\u00e9nys\u00e9ggel kell rendelkeznie.<\/p>\n\n\n\n

2. A tesztel\u0151t a tart\u00f3ss\u00e1g \u00e9s a pontoss\u00e1g \u00e9rdek\u00e9ben \u00e9p\u00edtett\u00e9k.<\/strong><\/h3>\n\n\n\n

Ezt a zselatin kem\u00e9nys\u00e9gm\u00e9r\u0151 k\u00e9sz\u00fcl\u00e9ket a n\u00e9met gy\u00e1rtm\u00e1ny\u00fa k\u00e9sz\u00fcl\u00e9kekn\u00e9l el\u00e9rhet\u0151 legnagyobb szabv\u00e1nyos pontoss\u00e1ggal fejlesztett\u00e9k ki. Emellett nagym\u00e9rt\u00e9kben reproduk\u00e1lhat\u00f3.<\/p>\n\n\n\n

Mi\u00e9rt fontos, hogy az eszk\u00f6z nagym\u00e9rt\u00e9kben reproduk\u00e1lhat\u00f3 legyen? A kapszul\u00e1kat t\u00e9telekben tesztelik, \u00e9s a t\u00e9telben mindegyiknek a t\u00f6bbihez hasonl\u00f3 tulajdons\u00e1gokkal \u00e9s kem\u00e9nys\u00e9ggel kell rendelkeznie.<\/p>\n\n\n\n

Nem szeretn\u00e9, ha a fogyaszt\u00f3 megfigyeln\u00e9 a k\u00fcl\u00f6nbs\u00e9geket, \u00e9s arra k\u00f6vetkeztetne, hogy a l\u00e1gyabbak lej\u00e1rtak, vagy nem eredeti term\u00e9ket kaptak. Csak akkor \u00e9rhet\u0151 el a legnagyobb fok\u00fa megb\u00edzhat\u00f3s\u00e1g, ha a kapszul\u00e1k nagym\u00e9rt\u00e9kben replik\u00e1ltak.<\/p>\n\n\n\n

A tudom\u00e1nyban a reproduk\u00e1lhat\u00f3s\u00e1g a prec\u00edzi\u00f3s vizsg\u00e1latok utols\u00f3 \u00e9s harmadik f\u00e1zisa. A stabilit\u00e1s el\u00e9r\u00e9se \u00e9rdek\u00e9ben a vizsg\u00e1lt term\u00e9kt\u0151l f\u00fcgg\u0151en egy jel\u00f6l\u0151rendszert v\u00e1lasztanak ki. A zselatinkapszul\u00e1k vizsg\u00e1latakor a sz\u00e1raz l\u00e1gy\u00edt\u00f3 a megfelel\u0151 s\u00falyar\u00e1ny.<\/p>\n\n\n\n

A sz\u00e1raz zselatin \u00e9s a v\u00edz ar\u00e1nya 1:1, a sz\u00e1raz zselatin pedig 0,4-0,6:1,0. Ha a kapott s\u00falyar\u00e1ny 1,8:1, ez azt jelenti, hogy a h\u00e9j puha. A l\u00e1gy\u00edt\u00f3 \u00e9s a zselatin k\u00f6z\u00f6tti s\u00falyar\u00e1nynak 0,3:1,0-nak kell lennie ahhoz, hogy a kapszula a legkem\u00e9nyebb form\u00e1j\u00e1t \u00e9rje el.<\/p>\n\n\n\n

3. Alkalmas k\u00fcl\u00f6nb\u00f6z\u0151 ipar\u00e1gakhoz - gy\u00f3gyszeripar<\/strong><\/h3>\n\n\n\n

A tablettakem\u00e9nys\u00e9g-ellen\u0151rz\u0151t els\u0151sorban a gy\u00f3gyszeriparban haszn\u00e1lj\u00e1k. Ez a laborat\u00f3riumi vizsg\u00e1lat meghat\u00e1rozza a tabletta szerkezeti integrit\u00e1s\u00e1t \u00e9s t\u00f6r\u00e9spontj\u00e1t. Meghat\u00e1rozza, hogyan v\u00e1ltozik a kezel\u00e9s, csomagol\u00e1s, sz\u00e1ll\u00edt\u00e1s \u00e9s t\u00e1rol\u00e1s sor\u00e1n. Az alak hat\u00e1rozza meg a tabletta t\u00f6r\u00e9spontj\u00e1t.<\/p>\n\n\n\n

Ez a fajta teszter m\u00e1r az 1930-as \u00e9vek \u00f3ta l\u00e9tezik. De csak 1953-ban szabadalmaztatta Robert Albrecht, \u00e9s Strong-Cobb tesztel\u0151nek nevezte el. Abban az id\u0151ben l\u00e9gszivatty\u00fak\u00e9nt haszn\u00e1lt\u00e1k.<\/p>\n\n\n\n

A tesztel\u0151k r\u00e9gebbi modelljeivel az volt a probl\u00e9ma, hogy az eredm\u00e9nyek nem voltak k\u00f6vetkezetesek. Ezt az \u00fajabb modellek, mint p\u00e9ld\u00e1ul a Gelomat, fel\u00fclm\u00falt\u00e1k.<\/p>\n\n\n\n

Ezt a j\u00f3l ismert k\u00e9sz\u00fcl\u00e9k a k\u00f6vetkez\u0151 funkci\u00f3k be\u00e9p\u00edt\u00e9se teszi lehet\u0151v\u00e9:<\/p>\n\n\n\n

Az automatikus m\u00e9r\u00e9si folyamat teljes integr\u00e1ci\u00f3ja<\/p>\n\n\n\n

Hiszter\u00e9zis funkci\u00f3<\/p>\n\n\n\n

Nagyfok\u00fa vizsg\u00e1lati hat\u00e9konys\u00e1got \u00e9s a legmagasabb szint\u0171 pontoss\u00e1got ny\u00fajtja.<\/p>\n\n\n\n

Egyedi tart\u00f3k\u00e9sz\u00fcl\u00e9kek<\/p>\n\n\n\n

K\u00e9nyelmes \u00e9s gyors adat\u00e1tvitel USB porton kereszt\u00fcl<\/p>\n\n\n\n

Felhaszn\u00e1l\u00f3bar\u00e1t rendszer, amelyet \u00fagy terveztek, hogy megfeleljen az ism\u00e9telhet\u0151s\u00e9g \u00e9s a legmagasabb szint\u0171 pontoss\u00e1gi el\u0151\u00edr\u00e1soknak.<\/p>\n\n\n\n

Automatikus korrekci\u00f3s funkci\u00f3<\/p>\n\n\n\n

Digit\u00e1lis kijelz\u0151 mutatja, ha a kapott \u00e9rt\u00e9kek a hat\u00e1r\u00e9rt\u00e9k alatt vagy felett vannak<\/p>\n\n\n\n

A digit\u00e1lis kijelz\u0151egys\u00e9g k\u00fcl\u00f6nb\u00f6z\u0151 funkci\u00f3kat k\u00e9pes ell\u00e1tni, bele\u00e9rtve az id\u0151 \u00e9s a tartom\u00e1ny m\u00e9r\u00e9s\u00e9t is.<\/p>\n\n\n\n

4. Alkalmas k\u00fcl\u00f6nb\u00f6z\u0151 ipar\u00e1gakhoz - paintball ipar<\/strong><\/h3>\n\n\n\n

Mire j\u00f3 egy kem\u00e9nys\u00e9gm\u00e9r\u0151 a paintball iparban? Hasonl\u00f3an ahhoz, amit a kapszul\u00e1kn\u00e1l kell el\u00e9rni, a paintballokn\u00e1l is sz\u00fcks\u00e9g van egy megism\u00e9telhet\u0151 \u00e9s megb\u00edzhat\u00f3 m\u00f3dszerre a goly\u00f3szed\u0151k, a hord\u00f3k \u00e9s a markerek vizsg\u00e1lat\u00e1hoz. A vizsg\u00e1lati rendszernek pontoss\u00e1got, megism\u00e9telhet\u0151s\u00e9get \u00e9s egyszer\u0171s\u00e9get kell biztos\u00edtania.<\/p>\n\n\n\n

Ebben az ipar\u00e1gban kulcsfontoss\u00e1g\u00fa a paintball r\u00f6pp\u00e1ly\u00e1j\u00e1t befoly\u00e1sol\u00f3 f\u00fcggetlen \u00e9s f\u00fcgg\u0151 v\u00e1ltoz\u00f3k elk\u00fcl\u00f6n\u00edt\u00e9se \u00e9s meghat\u00e1roz\u00e1sa. A labda pontoss\u00e1ga nagym\u00e9rt\u00e9kben f\u00fcgg a min\u0151s\u00e9g\u00e9t\u0151l. Csak akkor lehet egyenesen l\u0151ni a labd\u00e1t, ha az nem duzzadt, varratos vagy g\u00f6dr\u00f6s - olyan t\u00e9nyez\u0151k, amelyeket a tesztel\u0151 figyelembe vesz \u00e9s megszabadul t\u0151l\u00fck.<\/p>\n\n\n\n

A goly\u00f3 min\u0151s\u00e9ge mellett a cs\u0151 kem\u00e9nys\u00e9ge is meghat\u00e1rozza a bels\u0151 fel\u00fclet hossz\u00fa \u00e9lettartam\u00e1t. A hord\u00f3 lyukainak is megfelel\u0151 sz\u00f6g\u0171nek \u00e9s m\u00e9ret\u0171nek kell lenni\u00fck. A t\u00f6lt\u00e9shez sok gy\u00e1rt\u00f3 s\u0171r\u00edtett leveg\u0151t haszn\u00e1l, mert azt megb\u00edzhat\u00f3bbnak tal\u00e1lj\u00e1k, \u00e9s nagyobb pontoss\u00e1gi ar\u00e1nyt k\u00edn\u00e1l, mint a CO2.<\/p>\n\n\n\n

5. Alkalmas k\u00fcl\u00f6nb\u00f6z\u0151 ipar\u00e1gakhoz - kozmetikai ipar<\/strong><\/h3>\n\n\n\n

A kozmetikai iparban sz\u00e1mos olyan term\u00e9k van, amely sz\u00e1m\u00e1ra el\u0151ny\u00f6s, ha kem\u00e9nys\u00e9gvizsg\u00e1latnak vetik al\u00e1. Egy kozmetikai alapoz\u00f3 p\u00e9ld\u00e1ul az\u00e9rt megy \u00e1t a vizsg\u00e1laton, hogy biztos\u00edtsa, hogy nyom\u00e1sra el\u00e9g kem\u00e9ny legyen, \u00e9s megfeleljen a K+F \u00e9s a min\u0151s\u00e9gellen\u0151rz\u00e9s meghat\u00e1rozott szabv\u00e1nyainak. Ezt jellemz\u0151en egy olyan tesztel\u0151 seg\u00edts\u00e9g\u00e9vel v\u00e9gzik, amely szoftver, k\u00e1bel, teszt\u00e1llv\u00e1ny \u00e9s er\u0151m\u00e9r\u0151 m\u00e9r\u00e9sek felhaszn\u00e1l\u00e1s\u00e1val t\u00f6rt\u00e9nik. A teszter mechanikai tulajdons\u00e1gokkal rendelkezik, bele\u00e9rtve a leh\u00faz\u00e1si er\u0151t, a kompresszi\u00f3t \u00e9s a fesz\u00fclts\u00e9get.<\/p>\n\n\n\n

A kem\u00e9nys\u00e9gm\u00e9r\u0151 a kozmetikai term\u00e9kek min\u0151s\u00e9g\u00e9nek biztos\u00edt\u00e1s\u00e1ra is haszn\u00e1lhat\u00f3, bele\u00e9rtve a r\u00fazsokat, a szem\u00f6ld\u00f6k- vagy ajakceruz\u00e1kat, valamint a viasz- \u00e9s kr\u00e9mterm\u00e9keket. A kem\u00e9nys\u00e9gn\u00e9l jobban t\u00e1maszkodik az ipar a term\u00e9kek text\u00faratesztj\u00e9nek eredm\u00e9nyeire. Meg kell gy\u0151z\u0151dni\u00fck arr\u00f3l, hogy a kozmetikumok j\u00f3l \u00e9rzik magukat a b\u0151r\u00f6n, miel\u0151tt piacra dobn\u00e1k \u0151ket.<\/p>\n\n\n\n

6. Vizsg\u00e1lja az anyagokat h\u00faz\u00f3- \u00e9s nyom\u00f3szil\u00e1rds\u00e1gra<\/strong><\/h3>\n\n\n\n

A l\u00e1gy zsel\u00e9k vizsg\u00e1latakor a kapszula fal\u00e1nak szil\u00e1rds\u00e1g\u00e1t sz\u00e1mszer\u0171s\u00edtik, hogy meghat\u00e1rozz\u00e1k a felszakad\u00e1si pontot. Meghat\u00e1rozz\u00e1k a t\u00f6m\u00edt\u00e9s vagy a zselatin film gyenges\u00e9g\u00e9t is. A vizsg\u00e1latot az\u00e9rt v\u00e9gzik, hogy szimul\u00e1lj\u00e1k azokat a t\u00e9nyez\u0151ket, amelyek a kapszula felreped\u00e9s\u00e9t okozhatj\u00e1k, miel\u0151tt az a fogyaszt\u00f3hoz ker\u00fclne.<\/p>\n\n\n\n

A Gelomat nyom\u00f3er\u0151t alkalmaz a kapszul\u00e1kra, hogy adatokat gy\u0171jts\u00f6n arr\u00f3l, hogy azok megfeleltek-e a min\u0151s\u00e9gellen\u0151rz\u00e9sen. A k\u00e9sz\u00fcl\u00e9k a kapszul\u00e1k fal\u00e1nak szil\u00e1rds\u00e1g\u00e1t vizsg\u00e1lja, hogy a k\u00fcls\u0151 er\u0151k hat\u00e1s\u00e1ra is elegend\u0151-e a kapszula form\u00e1j\u00e1nak megtart\u00e1s\u00e1hoz.<\/p>\n\n\n\n

Az eszk\u00f6z c\u00e9lja, hogy a fogyaszt\u00f3k kez\u00e9be ne ker\u00fclj\u00f6n sziv\u00e1rg\u00f3 kapszula. Ez azt eredm\u00e9nyezi, hogy a fogyaszt\u00f3k nagyobb m\u00e9rt\u00e9kben b\u00edznak a gy\u00e1rt\u00f3kban, \u00e9s nagyobb ar\u00e1nyban fognak \u00fajra v\u00e1s\u00e1rolni.<\/p>\n\n\n\n

A kem\u00e9nys\u00e9gvizsg\u00e1lat csak egy a sz\u00e1mos vizsg\u00e1lat k\u00f6z\u00fcl, amelyen a term\u00e9kek, p\u00e9ld\u00e1ul a kapszul\u00e1k, a min\u0151s\u00e9gellen\u0151rz\u00e9s v\u00e9grehajt\u00e1sa \u00e9rdek\u00e9ben \u00e1tesnek. Ugyanez igaz a fest\u00e9kgoly\u00f3kra \u00e9s a kozmetikai term\u00e9kekre is. Mindezek a fogyaszt\u00f3k \u00e1ltal megv\u00e1s\u00e1rolni vagy elfogyasztani k\u00edv\u00e1nt term\u00e9kek egy sor vizsg\u00e1laton mennek kereszt\u00fcl, miel\u0151tt csomagolj\u00e1k \u00e9s eladj\u00e1k \u0151ket.<\/p>\n\n\n\n

A l\u00e1gyzsel\u00e9s kapszul\u00e1k eset\u00e9ben minden egyes t\u00e9tel sz\u00e1mos vizsg\u00e1laton megy kereszt\u00fcl annak meg\u00e1llap\u00edt\u00e1s\u00e1ra, hogy megfelelnek-e a rekl\u00e1mozott \u00e9s fogyaszt\u00e1sra elfogadhat\u00f3 szabv\u00e1nyoknak.<\/p>\n\n\n\n

7. A leg\u00fajabb technol\u00f3gi\u00e1t haszn\u00e1lja<\/strong><\/h3>\n\n\n\n

A r\u00e9gebbi modellekkel ellent\u00e9tben a k\u00f6zelm\u00faltban kifejlesztett kem\u00e9nys\u00e9gm\u00e9r\u0151 k\u00e9sz\u00fcl\u00e9kek, mint p\u00e9ld\u00e1ul a n\u00e9met gy\u00e1rtm\u00e1ny\u00fa Gelomat, integr\u00e1lt \u00e9rt\u00e9ket, hat\u00e9konys\u00e1got \u00e9s a leg\u00fajabb szabadalmaztatott technol\u00f3gi\u00e1t k\u00edn\u00e1lnak. A Gelomat haszn\u00e1lhat\u00f3 h\u00faskem\u00e9nys\u00e9gm\u00e9r\u0151, tejsz\u00ednkem\u00e9nys\u00e9gm\u00e9r\u0151, vajkem\u00e9nys\u00e9gm\u00e9r\u0151, \u00e9s m\u00e9g sok minden m\u00e1s. Ez mutatja, hogy a gy\u00e1rt\u00f3k mennyire komolyan veszik, hogy \u00fcgyfeleik a legjobb term\u00e9keket kapj\u00e1k.<\/p>\n\n\n\n

A Gelomat pontos digit\u00e1lis m\u00e9r\u0151rendszereket \u00e9s egyedi kialak\u00edt\u00e1st alkalmaz, hogy megk\u00f6nny\u00edtse a folyamatot an\u00e9lk\u00fcl, hogy a vizsg\u00e1lati eredm\u00e9nyek fel\u00e1ldozn\u00e1k. A zselatinkapszul\u00e1k kem\u00e9nys\u00e9g\u00e9nek automatikus m\u00e9r\u00e9se olyan rendszeren kereszt\u00fcl t\u00f6rt\u00e9nik, amely megb\u00edzhat\u00f3an biztos\u00edtja az optim\u00e1lis ism\u00e9telhet\u0151s\u00e9get \u00e9s pontoss\u00e1got.<\/p>\n\n\n\n

A Gelomat rendszer az egyik egyetlen olyan rendszer a vil\u00e1gon, amely az \u00fcgyfelek egyedi vizsg\u00e1lati k\u00f6vetelm\u00e9nyeinek megfelel\u0151 egyedi r\u00f6gz\u00edt\u0151elemek \u00e9s \u00fcll\u0151k kifejleszt\u00e9se r\u00e9v\u00e9n a legnagyobb rugalmass\u00e1gra k\u00e9pes. Ez teszi a Gelomat rendszert egyed\u00fcl\u00e1ll\u00f3 megold\u00e1scsomagg\u00e1.<\/p>\n\n\n\n

8. A tablett\u00e1k kem\u00e9nys\u00e9g\u00e9nek sz\u00e1mszer\u0171s\u00edt\u00e9s\u00e9nek megk\u00f6nny\u00edt\u00e9se<\/strong><\/h3>\n\n\n\n

A szil\u00e1rd tablett\u00e1k a gy\u00f3gyszerekben haszn\u00e1lt leggyakoribb adagol\u00e1si forma. A tablett\u00e1k kem\u00e9nys\u00e9ge a term\u00e9k min\u0151s\u00e9gellen\u0151rz\u00e9s\u00e9nek el\u0151\u00edr\u00e1sait \u00e9s a term\u00e9kfejleszt\u00e9s krit\u00e9riumait tartalmazza.<\/p>\n\n\n\n

A tabletta kem\u00e9nys\u00e9gm\u00e9r\u0151nek min\u0151s\u00e9gi eredm\u00e9nyeket kell kapnia a term\u00e9kb\u0151l, ami azt jelenti, hogy az egyes tablett\u00e1k nem t\u00fal puh\u00e1k \u00e9s nem t\u00fal kem\u00e9nyek.<\/p>\n\n\n\n

Ha egy tabletta t\u00fal puha, akkor a beteg \u00e1ltal bev\u00e9ve a korai sz\u00e9tes\u00e9shez vezethet. Ez a gyenge k\u00f6t\u00e9s k\u00f6vetkezt\u00e9ben t\u00f6rt\u00e9nhet. Ezenk\u00edv\u00fcl a t\u00fal l\u00e1gy tabletta a csomagol\u00e1s, a bevonatol\u00e1s \u00e9s m\u00e1s gy\u00e1rt\u00e1si szakaszok sor\u00e1n elt\u00f6rhet vagy let\u00f6rhet.<\/p>\n\n\n\n

M\u00e1sr\u00e9szt, ha a tabletta rendk\u00edv\u00fcl kem\u00e9ny, az a megfelel\u0151 adag nem megfelel\u0151 felold\u00f3d\u00e1s\u00e1hoz vezethet, amint a beteg beveszi. A probl\u00e9ma gy\u00f6kere a seg\u00e9danyagok \u00e9s a hat\u00f3anyagok k\u00f6z\u00f6tti t\u00fal nagy k\u00f6t\u00e9si potenci\u00e1lban gy\u00f6kerezhet.<\/p>\n\n\n\n

A tabletta kem\u00e9nys\u00e9g\u00e9nek vizsg\u00e1lata sz\u00e1mszer\u0171s\u00edti, hogy a term\u00e9k fogyaszthat\u00f3-e, \u00e9s megfelelt-e a legmagasabb min\u0151s\u00e9gi k\u00f6vetelm\u00e9nyeknek. Ugyanakkor az optim\u00e1lis eredm\u00e9nyekhez sz\u00fcks\u00e9ges \u00f6sszes mechanikai tulajdons\u00e1got is tartalmaznia kell. A gy\u00e1rt\u00f3nak l\u00e1tnia kell, hogy a term\u00e9kben a megfelel\u0151 \u00f6sszet\u00e9tel\u0171 \u00f6sszetev\u0151ket, a hat\u00f3anyagok jelleg\u00e9t \u00e9s a felhaszn\u00e1lt k\u00f6t\u0151anyagokat haszn\u00e1lt\u00e1k-e fel. Ezeket a t\u00e9nyez\u0151ket m\u00e9g a gy\u00e1rt\u00e1s sor\u00e1n ellen\u0151rizni\u00fck kell, hogy n\u00f6velj\u00e9k annak es\u00e9ly\u00e9t, hogy a v\u00e9gleges tabletta \u00e1tmenjen a kem\u00e9nys\u00e9gvizsg\u00e1laton.<\/p>\n\n\n\n

9. Biztos\u00edtja a leg\u00fajabb ipari szabv\u00e1nyoknak val\u00f3 szigor\u00fa megfelel\u00e9st<\/strong><\/h3>\n\n\n\n

A zselatinkapszul\u00e1k eset\u00e9ben a k\u00e9szterm\u00e9keket teszteknek kell al\u00e1vetni. Tal\u00e1n m\u00e1r hallott olyan kifejez\u00e9sekr\u0151l, mint a kapszula kem\u00e9nys\u00e9gtesztel\u0151 vagy a zselatin kem\u00e9nys\u00e9gtesztel\u0151.<\/p>\n\n\n\n

A kapszul\u00e1kat sz\u00e1mos vizsg\u00e1latnak vetik al\u00e1, hogy megfeleljenek a szab\u00e1lyoz\u00e1si k\u00f6vetelm\u00e9nyeknek \u00e9s az \u00f6sszet\u00e9teli szabv\u00e1nyoknak. A vizsg\u00e1latok eredm\u00e9nyei hat\u00e1rozz\u00e1k meg, hogy a t\u00e9tel megfelelt-e a tervezett felhaszn\u00e1l\u00e1sra \u00e9s forgalomba hozatalra.<\/p>\n\n\n\n

10. A k\u00f6zbizalom elnyer\u00e9se<\/strong><\/h3>\n\n\n\n

Mi\u00e9rt van sz\u00fcks\u00e9g ezekre a vizsg\u00e1latokra? Ezek a term\u00e9kek nagym\u00e9rt\u00e9kben f\u00fcggnek a fogyaszt\u00f3k bizalm\u00e1t\u00f3l. A sziv\u00e1rg\u00f3 kapszul\u00e1k negat\u00edvan befoly\u00e1solhatj\u00e1k az emberek v\u00e9lem\u00e9ny\u00e9t a term\u00e9kr\u0151l \u00e9s az ugyanatt\u00f3l a gy\u00e1rt\u00f3t\u00f3l sz\u00e1rmaz\u00f3 \u00f6sszes t\u00f6bbi term\u00e9kr\u0151l.<\/p>\n\n\n\n

Ez\u00e9rt fontos, hogy a hib\u00e1s kapszul\u00e1k ne ker\u00fcljenek a piacra; ez\u00e9rt a gy\u00e1rt\u00f3k l\u00e1gy kapszula kem\u00e9nys\u00e9gtesztel\u0151t haszn\u00e1lnak, hogy biztos\u00edts\u00e1k, hogy a piacon megjelen\u0151 \u00f6sszes term\u00e9k\u00fck nem vesz\u00e9lyezteti a nev\u00fcket.<\/p>\n\n\n\n

V\u00e9gs\u0151 gondolatok<\/h2>\n\n\n\n

Az \u00d6n min\u0151s\u00e9gellen\u0151rz\u0151 l\u00e9tes\u00edtm\u00e9nye sz\u00e1mos el\u0151nyre tesz szert a l\u00e1gyzsel\u00e9 kem\u00e9nys\u00e9gm\u00e9r\u0151 haszn\u00e1lat\u00e1val, de a tesztelt \u00e9s min\u0151s\u00e9gi eszk\u00f6z\u00f6kre kell t\u00e1maszkodnia. Err\u0151l ismert a Bareiss, a v\u00e1llalat, amely 1954-es alap\u00edt\u00e1sa \u00f3ta elk\u00f6telezett a technol\u00f3gia \u00e9s az innov\u00e1ci\u00f3 ir\u00e1nt.<\/p>\n\n\n\n

Tesztel\u00e9s: Mennyire sziv\u00e1rg\u00e1sbiztosak a kapszul\u00e1k?<\/h2>\n\n\n\n

A sziv\u00e1rg\u00f3 zselatinkapszul\u00e1k cs\u00f6kkentik a fogyaszt\u00f3k bizalm\u00e1t a term\u00e9k \u00e9s a gy\u00e1rt\u00f3 ir\u00e1nt. Annak \u00e9rdek\u00e9ben, hogy a hib\u00e1s kapszul\u00e1k ne ker\u00fclhessenek a piacra, teszteket kell kidolgoznia a hib\u00e1s kapszul\u00e1k azonos\u00edt\u00e1s\u00e1ra. Az egyik megk\u00f6zel\u00edt\u00e9s egy olyan text\u00faraelemz\u0151 m\u0171szer haszn\u00e1lata, amely h\u00faz\u00f3- \u00e9s nyom\u00f3er\u0151t alkalmaz a zselatinkapszul\u00e1kra, hogy meger\u0151s\u00edtse, hogy a kapszul\u00e1k fal\u00e1nak szil\u00e1rds\u00e1ga elegend\u0151 ahhoz, hogy ellen\u00e1lljon a k\u00fcls\u0151 er\u0151knek a gy\u00e1rt\u00e1s, t\u00e1rol\u00e1s, csomagol\u00e1s \u00e9s sz\u00e1ll\u00edt\u00e1s sor\u00e1n. <\/p>\n\n\n\n

A kapszul\u00e1s gy\u00f3gyszerk\u00e9sz\u00edtm\u00e9nyek formul\u00e1z\u00e1sakor fontos tudni, hogy a t\u00f6ltel\u00e9k - mind a hat\u00f3anyag, mind a seg\u00e9danyagok - kompatibilisek-e a zselatinh\u00e9jjal, amely v\u00edzoldhat\u00f3 feh\u00e9rj\u00e9k kever\u00e9k\u00e9b\u0151l \u00e1ll. B\u00e1rmilyen aldehideket (pl. formaldehidet) tartalmaz\u00f3 anyag a zselatin keresztk\u00f6t\u00e9s\u00e9t okozhatja, a zselatinsz\u00e1lakon bel\u00fcl \u00e9s a zselatinsz\u00e1lak k\u00f6z\u00f6tt lizinmaradv\u00e1nyokkal. Ez megmerev\u00edti a zselatin szerkezet\u00e9t \u00e9s lass\u00edtja a sz\u00e9tes\u00e9s\u00e9t. Az is fontos, hogy megismerj\u00fck, hogyan l\u00e9p k\u00f6lcs\u00f6nhat\u00e1sba a t\u00f6ltel\u00e9k a zselatinh\u00e9j v\u00edztartalm\u00e1val. Az er\u0151sen higroszk\u00f3pos t\u00f6ltel\u00e9k p\u00e9ld\u00e1ul vizet sz\u00edvhat fel a h\u00e9jb\u00f3l, ami t\u00f6r\u00e9kenny\u00e9 \u00e9s t\u00f6r\u00e9sre hajlamosabb\u00e1 teheti azt. <\/p>\n\n\n\n

A text\u00faraelemz\u0151 k\u00e9sz\u00fcl\u00e9k sz\u00e1mszer\u0171s\u00edti a mechanikai szil\u00e1rds\u00e1got a kem\u00e9ny zselatin kapszula<\/a> h\u00e9jakat, \u00edgy felm\u00e9rheti, hogy a k\u00fcl\u00f6nb\u00f6z\u0151 t\u00f6ltetek hogyan befoly\u00e1solj\u00e1k a kapszula szil\u00e1rds\u00e1g\u00e1t \u00e9s stabilit\u00e1s\u00e1t. Mindezt \u00fagy teszi, hogy ellen\u0151rz\u00f6tt mechanikai felt\u00e9teleket alkalmaz a mint\u00e1ra, majd sz\u00e1mszer\u0171s\u00edti az \u00edgy kialakul\u00f3 viselked\u00e9st. Az, hogy a mint\u00e1k hogyan reag\u00e1lnak, k\u00f6zvetlen\u00fcl kapcsol\u00f3dik a fizikai jellemz\u0151ikhez, \u00e9s val\u00f3s k\u00e9pet ad a bels\u0151 szerkezet\u00fckr\u0151l. <\/p>\n\n\n\n

A text\u00faraelemz\u0151 k\u00e9sz\u00fcl\u00e9k h\u00faz\u00f3- vagy nyom\u00f3 \u00fczemm\u00f3dban m\u0171k\u00f6dik, \u00e9s ciklikus vizsg\u00e1latokat v\u00e9gezhet, amelyek sor\u00e1n t\u00f6bbsz\u00f6r is deform\u00e1ci\u00f3s hat\u00e1st fejt ki. A m\u0171szer \u00e1ltal\u00e1ban grammban m\u00e9ri a terhel\u00e9si er\u0151t, \u00e9s \u00f6sszekapcsolja azt a kapszula deform\u00e1ci\u00f3j\u00e1val. Az eredm\u00e9nyeket grafikus form\u00e1ban, az er\u0151 \u00e9s az id\u0151 vagy az er\u0151 \u00e9s a t\u00e1vols\u00e1g f\u00fcggv\u00e9ny\u00e9ben mutatja be. A deform\u00e1ci\u00f3 sor\u00e1n k\u00fcl\u00f6nb\u00f6z\u0151 textur\u00e1lis param\u00e9terek j\u00e1tszhatnak szerepet, \u00e9s ezeket a vizsg\u00e1lat \u00e1ltal gener\u00e1lt er\u0151-alakv\u00e1ltoz\u00e1s g\u00f6rb\u00e9n lehet megfigyelni. Az elm\u00falt 40 \u00e9vben sz\u00e1mos, text\u00faraelemz\u00e9st alkalmaz\u00f3 tudom\u00e1nyos tanulm\u00e1ny korrel\u00e1lta ezeket a viselked\u00e9seket az \u00e9rz\u00e9kszervi jellemz\u0151kkel. <\/p>\n\n\n\n

Kapszula-hurok szak\u00edt\u00f3vizsg\u00e1lat <\/h2>\n\n\n\n

Ha a text\u00faraelemz\u0151t a fenti k\u00e9pen l\u00e1that\u00f3 kapszulahurok-h\u00faz\u00f3szerkezettel szereli fel, \u00f6sszehasonl\u00edthatja az \u00fcres kapszulah\u00e9jak mechanikai szil\u00e1rds\u00e1g\u00e1t. A gyakorlatban a r\u00f6gz\u00edt\u0151 k\u00e9t v\u00e9kony r\u00fadj\u00e1t a kapszulah\u00e9j egyik fel\u00e9be, \u00e1ltal\u00e1ban a kupakba helyezik. Az als\u00f3 rudat ezut\u00e1n a m\u0171szeralaphoz r\u00f6gz\u00edtik, m\u00edg a fels\u0151 rudat az analiz\u00e1tor meghajt\u00f3 mechanizmus\u00e1hoz r\u00f6gz\u00edtik. A meghajt\u00f3 a fels\u0151 rudat egyenletes sebess\u00e9ggel, jellemz\u0151en 0,1 \u00e9s 1,0 millim\u00e9ter\/m\u00e1sodperc k\u00f6z\u00f6tt emeli, \u00e9s ezzel meghat\u00e1rozott t\u00e1vols\u00e1gra ny\u00fajtja a kapszulah\u00e9jat. Bizonyos esetekben a vizsg\u00e1lat a kapszulah\u00e9j megreped\u00e9s\u00e9t okozza. <\/p>\n\n\n\n

T\u00f6m\u00f6r\u00edt\u00e9si teszt <\/h2>\n\n\n\n

A text\u00faraelemz\u0151 k\u00e9sz\u00fcl\u00e9k k\u00e9t vizsg\u00e1lati m\u00f3dszerrel is k\u00e9pes m\u00e9rni a l\u00e1gyzselatin kapszula (softgel) nyom\u00f3szil\u00e1rds\u00e1g\u00e1t. Az els\u0151ben egy 36 millim\u00e9ter \u00e1tm\u00e9r\u0151j\u0171 szonda seg\u00edts\u00e9g\u00e9vel sz\u00e1mszer\u0171s\u00edtik a t\u00f6m\u00edt\u0151szil\u00e1rds\u00e1got (2. \u00e1bra), a m\u00e1sodikban - a behatol\u00e1svizsg\u00e1latban - pedig egy 2 millim\u00e9teres hengeres szonda hat\u00e1rozza meg a l\u00e1gyzsel\u00e9 felszakad\u00e1si pontj\u00e1t. A k\u00e9t vizsg\u00e1lat nemcsak a l\u00e1gyzsel\u00e9 szil\u00e1rds\u00e1g\u00e1nak gyenge pontjait azonos\u00edtja, hanem szimul\u00e1lja azokat a k\u00f6r\u00fclm\u00e9nyeket, amelyek k\u00f6z\u00f6tt a l\u00e1gyzsel\u00e9 kiszakadhat a csomagol\u00e1s vagy a sz\u00e1ll\u00edt\u00e1s sor\u00e1n. B\u00e1rmely kapszula - legyen az kem\u00e9ny vagy l\u00e1gy - t\u00f6m\u00edt\u00e9si szil\u00e1rds\u00e1g\u00e1nak m\u00e9r\u00e9sekor olyan t\u00f6m\u00f6r\u00edt\u0151 szond\u00e1t haszn\u00e1ljon, amelynek \u00e1tm\u00e9r\u0151je nagyobb, mint a kapszula, \u00e9s a t\u00f6m\u00edt\u00e9st a szond\u00e1ra \u00e9s az alkalmazott er\u0151re mer\u0151legesen igaz\u00edtsa. L\u00e1sd az al\u00e1bbi k\u00e9pet. A 2. t\u00e1bl\u00e1zat a l\u00e1gykapszula kem\u00e9nys\u00e9gvizsg\u00e1latainak eredm\u00e9nyeit tartalmazza.<\/p>\n\n\n\n

G\u00e9l szil\u00e1rds\u00e1gi teszt <\/h2>\n\n\n\n

A zselatint sz\u00e1mos ipar\u00e1gban \u00e9s sz\u00e1mos k\u00fcl\u00f6nb\u00f6z\u0151 alkalmaz\u00e1sban haszn\u00e1lj\u00e1k, \u00e9s szinte minden esetben mind a zselatin gy\u00e1rt\u00f3ja, mind a v\u00e9gfelhaszn\u00e1l\u00f3 m\u00e9ri a zselatin szil\u00e1rds\u00e1g\u00e1t, ami a hat\u00e9konys\u00e1got jelzi. A g\u00e9l szil\u00e1rds\u00e1ga nagym\u00e9rt\u00e9kben f\u00fcgg a vir\u00e1gz\u00e1s er\u0151ss\u00e9g\u00e9t\u0151l. A k\u00f6vetkez\u0151 oldalon l\u00e1that\u00f3 k\u00e9pen egy zselatinmint\u00e1t tartalmaz\u00f3, vizsg\u00e1latra k\u00e9sz zselatinos t\u00e9gely l\u00e1that\u00f3. <\/p>\n\n\n\n

Egy szabv\u00e1nyos bloom szond\u00e1val, bloom palackokkal \u00e9s zselatinf\u00fcrd\u0151vel felszerelt text\u00faraelemz\u0151 k\u00e9sz\u00fcl\u00e9kkel egyszer\u0171 vizsg\u00e1latokat v\u00e9gezhet, \u00e9s gyorsan \u00e9s pontosan meghat\u00e1rozhatja a g\u00e9l szil\u00e1rds\u00e1g\u00e1t, amelyet a g\u00e9l meghat\u00e1rozott t\u00e1vols\u00e1gon kereszt\u00fcli deform\u00e1ci\u00f3j\u00e1hoz sz\u00fcks\u00e9ges er\u0151k\u00e9nt m\u00e9rnek.<\/p>\n\n\n\n

A text\u00faraelemz\u0151 k\u00e9sz\u00fcl\u00e9kkel a zselatin zsel\u00e9sed\u00e9si szil\u00e1rds\u00e1g\u00e1t a \u201cMintav\u00e9telez\u00e9s \u00e9s zselatinvizsg\u00e1lat\u201d (BS757: 1975) brit szabv\u00e1nyos m\u00f3dszerrel, vagy a Gelatin Manufacturers Institute of America (GMIA) vagy az Eur\u00f3pai Zselatingy\u00e1rt\u00f3k Sz\u00f6vets\u00e9ge (Gelatine Manufacturers of Europe) szabv\u00e1nyainak alkalmaz\u00e1s\u00e1val lehet meghat\u00e1rozni, amely 1998-ban elfogadta a GMIA szabv\u00e1nyt. Ennek eredm\u00e9nyek\u00e9ppen minden jelenlegi m\u00f3dszer egy 12,7 millim\u00e9ter \u00e1tm\u00e9r\u0151j\u0171, \u00e9les sz\u00e9l\u0171, lapos fel\u00fclet\u0171, hengeres szonda haszn\u00e1lat\u00e1t \u00edrja el\u0151. (Az eur\u00f3pai m\u00f3dszer az \u00e9les \u00e9l helyett kis sugar\u00fa szond\u00e1t \u00edrt el\u0151). <\/p>\n\n\n\n

Ez a m\u00f3dszer m\u00e1s kapszulah\u00e9j-anyagok, p\u00e9ld\u00e1ul HPMC eset\u00e9ben is alkalmazhat\u00f3. Nagy mechanikai szil\u00e1rds\u00e1g\u00fa mint\u00e1k vizsg\u00e1latakor fontolja meg egy nagyobb kapacit\u00e1s\u00fa terhel\u00e9sm\u00e9r\u0151 cella haszn\u00e1lat\u00e1t. Hasonl\u00f3k\u00e9ppen, a nagy rugalmass\u00e1g\u00fa komponenssel rendelkez\u0151 mint\u00e1k eset\u00e9ben sz\u00fcks\u00e9g lehet a vizsg\u00e1lati t\u00e1vols\u00e1g meghosszabb\u00edt\u00e1s\u00e1ra. <\/p>\n\n\n\n

K\u00f6vetkeztet\u00e9s <\/h2>\n\n\n\n

By identifying key characteristics that affect the finished product, texture analysis is an integral part of R&D, process optimization, and production. It helps guide your choices during the initial stages of development and provides at-line process control. By setting high and low limits of acceptance, texture analysis enables you to optimize manufacturing and reduce waste. <\/p>\n\n\n\n

Challenges of Dissolution Methods Development for Soft Gelatin Capsules<\/h2>\n\n\n\n

Noyes and Whitney first documented the study of the dissolution process in 1897 as a field of physical chemistry, which later was mimicked in pharmacy due to its importance in drug administration [74]. The dissolution of solid dosage forms attracted attention as the realization of the importance of drug dissolution concerning bioavailability was identified in the 1950s with the understanding that only dissolved drugs can diffuse through the human body [74,75,76,77,78]. Poor drug solubility and low dissolution rates potentially lead to insufficient availability of the drug at the site of action and subsequent failure of the in vivo therapeutic performance. This is independent of the fact that the drug could be an ideal structure for the target site. Essentially, if the drug is too insoluble, it can never reach its target site, and it will be of no therapeutic relevance. Characterization of the dissolution of a drug from a given dosage form is critical for the successful development of a drug product. This section discusses the current state-of-the-art of SGCs dissolution and various practical concepts of developing dissolution methods for SGCs.<\/p>\n\n\n\n

Dissolution testing is an official test used for evaluating the rate of drug release from a dosage form into the dissolution medium or solvent under standardized conditions of liquid\/solid interface, temperature, paddle speed, or solvent composition. Dissolution testing has become important in measuring the in vitro rate and extent of API release from different dosage forms, including SGCs. Dissolution can be described as a process by which molecules of a solute (e.g., API) are dissolved in a solvent to form a solution. The in vivo effectiveness of a dosage form depends on its ability to release the drug for systemic absorption. SGCs dissolution goes through three main steps, the first one being swelling and rupture of the gelatin shell, followed by release and dispersion of the fill material, and finally, the dissolution of the active ingredient(s) in the dissolution medium ( ). These processes occur in series, and thus the slowest step determines dissolution rate of the SGCs. The slowest step in this case controls the overall rate and extent of drug absorption. However, this varies from drug to drug. For poorly soluble drugs, especially BCS II and IV, their dissolution will be a rate-limiting step in the absorption process. On the other hand, for drugs that have high solubility, their dissolution will be rapid, and rate and extent of absorption can be affected by other factors, e.g., membrane permeability, enzymes degradation in the GIT, or first pass metabolism.<\/p>\n\n\n\n

A critical requirement for drug products is that they release the APIs in vivo at a predictable rate [ 9 , 82 , 83 ]. The kinetics of drug release follows the release mechanism of the system, such as diffusion through the inert matrix, diffusion across the gel, osmotic release, ion-exchange, or pH-sensitive delivery systems. Among the various mechanisms involved in API release, diffusion is the principal release mechanism, and it takes place at varying degrees in every system. Solute release models in physical chemistry preceded the development of drug delivery systems by many years [ 77 , 78 ]. In 1961, Higuchi introduced a mathematical model of drug release for diffusion-controlled systems [ 84 ]. The author analyzed the release kinetics of an ointment, assuming that it is homogeneously dispersed and is released in the planar matrix and the medium. According to the model, the release mechanism is proportional to the square root of time [ 85 ]. This model is recommended for the initial 60% of the release curve due to its approximate nature. In late 1969, Wang published an article considering the two independent mechanisms of transport, Fick\u2019s law, and polymer relaxation on the molecules\u2019 movement in the matrix [ 86 ]. Then, Peppas, in 1985, introduced a semi-empirical equation, power law, to describe drug release from polymeric devices in a generalized way [ 87 , 88 ].<\/p>\n\n\n\n

Another concept that needs to be introduced here is the drug release phenomenon. Drug dissolution rates and drug release rates are quite different. Drug release refers to the process by which the drug in a drug product is released in the dissolution medium or at the site of absorption by diffusion or dissolution of a drug product. Depending on the physical form of the API in the drug product, the release of API may be slow or immediate. As described in the previous section, dissolution is a process by which molecules of a solute are dissolved in solvent vehicles as a function of time. On the other hand, the term \u201crelease\u201d most often refers to a much more complex phenomenon. Release encompasses capsule dissolution as one of its several steps. Upon contact with the aqueous medium, water penetrates the soft gelatin shell and at least partially dissolves the API [ 81 ]. Then, the dissolved API diffuses out through the capsule shell due to concentration gradients. Furthermore, the gelatin shell might undergo significant swelling as soon as the critical water content is reached, which will result in the rupture of the shell, followed by dispersion and eventual dissolution in the release medium. Hence, several steps are involved in the process of releasing the API from SGCs drug products, with only one of them being drug dissolution.<\/p>\n\n\n\n

The dissolution rate of a drug product in each solvent is defined as the rate of transfer of individual drug molecules from the solid particles into the solution as individual molecules, and it can be expressed as the concentration of dissolved API for a given time interval. The rate of dissolution can vary depending on the form of API, e.g., the amorphous form usually has rapid dissolution compared to crystalline forms of API [ 79 , 80 ].<\/p>\n\n\n\n

Another important thermodynamic property in a discussion of dissolution processes is solubility, which may be expressed in several ways, including but not limited to molarity, molality, mole fraction, mole ratio, and parts per million. As an illustration, for the case of a drug molecule, consider an excess amount of solid that is exposed to the solvent phase at a defined temperature and pressure. In the equilibrium state, the number of drug molecules going into the solution equals the number of drug molecules which re-precipitate. Under these conditions, the solution is saturated with drug molecules and the concentration of dissolved drug under these conditions is defined as the \u201cequilibrium drug solubility\u201d (specific to the given temperature and pressure) [ 89 ]. It is important to assure that the solid phase present at the beginning of the experiment remains unaltered after reaching thermodynamic equilibrium during any solubility experiment. It is worth mentioning that, when particle size or the presence of additives, or the pH modifies the intrinsic solubility, this is usually reported as \u201capparent solubility\u201d to distinguish it from the equilibrium value. In order to avoid the inconsistency in solubility data reporting, the size of filters used in the separation of dissolved drug particles must be stated.<\/p>\n\n\n\n

However, the USP General Chapter , Disintegration and dissolution of dietary supplements, accepts a rupture test as a performance test of SGCs if the capsule content is semi-solid or liquid [ 92 ]. The rupture test is performed using apparatus 2, as described under General Chapter Dissolution , at a rotation speed of 50 rpm in 500 mL of immersion medium for a duration of 15 min. As per USP , the requirements are met if all of the SGCs tested rupture in not more than 15 min\u201d. If 1 or 2 of the SGCs rupture in more than 15 min but not more than 30 min, the test is repeated on 12 additional SGCs: not more than 2 of the total of 18 capsules tested rupture in more than 15 but not more than 30 min. For SGCs that do not conform to the above rupture test acceptance criteria, the test is repeated with the addition of papain to the medium in the amount that results in an activity of not more than 550,000 units\/L of medium or with the addition of bromelain in the amount that results in an activity of not more than 30 gelatin-digesting units\/L of medium [ 92 ]. Almukainzi et al. [ 93 ] compared the rupture and disintegration tests of SGCs of amantadine, ginseng, flaxseed oil, pseudoephedrine hydrochloride, and soybean oil. Their data showed that neither rupture test nor disintegration test was advantageous over the other. However, rupture test reached the endpoint quicker compared to the disintegration test. In another study, Bachour et al. [ 94 ] evaluated the suitability of the rupture test for stability studies of SGCs containing oil-based oral multivitamins. Their study showed that the rupture test was sensitive to stability conditions, and that the commercial drug products passed the rupture test. However, all long-term stability samples failed the rupture test using tier 2 conditions. This indicates that the rupture test may be suitable for assessing the performance of some drug products, but this will depend on the properties of fill components.<\/p>\n\n\n\n

The disintegration test is considered as one of the performance tests for the immediate release dosage forms [ 90 ]. As per the USP , disintegration is defined as \u201cthe state in which any residue of the unit, except fragments of insoluble coating or capsule shell, remaining on the screen of the test apparatus or adhering to the lower surface of the disk, if used, is a soft mass having no palpably firm core\u201d [ 91 ]. The requirements of disintegration are met if all test units have completely disintegrated or if not fewer than 16 of a total of 18 units tested are disintegrated within a predetermined time period. This does not imply complete solution of the API or the drug product.<\/p>\n\n\n\n

6.5. Practical Concepts of Developing a Dissolution Method<\/h3>\n\n\n\n

Dissolution testing is used throughout drug product development as an indicator of drug product performance. During formulation development, dissolution testing is used to demonstrate the release and uniformity of a dosage form in a simulated environment. Once the performance is established for the product, this information is used periodically during stability to determine if the characteristics of the product are changing in such a way that the product continues to or stops performing as required. Often, the performance of a drug product in dissolution shows physical behavior; however, it does not necessarily indicate performance in vivo. Therefore, correlation between dissolution and pharmacokinetic data can be used to demonstrate if dissolution testing has the ability to predict drug performance. This is referred to as establishing in vitro\u2013in vivo correlation (IVIVC) [95].<\/p>\n\n\n\n

The purpose of this section is to give an overview of the practical concepts of developing dissolution test methods for SGCs. It is important to understand that the dissolution of a product requires a number of physical changes to take place. Unlike other typical solid dose forms, SGCs must first reach the point where the integrity of the gelatin is compromised and the outer shell ruptures to allow release of the fill material. Following this, the fill components must disperse within the media to allow the active ingredients to either enter solution or distribute evenly throughout the media ( ). The challenge is that the capsule shell is very sensitive to its environment and can change relative to hardness, cross-linking, and seam integrity, which can all play a role in perceived dissolution changes when in fact they are changes in rupture time. Therefore, it is essential to develop a dissolution strategy that accounts for differences in the integrity of the capsule shell as well as changes in the fill material.<\/p>\n\n\n\n

Dissolution methods development are labor-intensive processes even with careful technique and practice. It is important to invest time in developing a procedure that can be efficiently executed on a routine basis and repeated robustly. Dissolution tests are required by the Pharmacopeias to determine the release of the drug from the dosage form in an environment with a pH from 1.2 to 7.4. For example, USP [96] requires a two-step dissolution method for enteric-coated solid oral dosage forms that demonstrates coating integrity in an acidic environment, usually 0.1 N HCl, followed by exposure to a neutral pH environment, preferably with a phosphate buffer, where the first step of dissolution method provides information about the coating quality and the potential for coating failure. The United States Pharmacopeia (USP) and the U.S. Food and Drug Administration (FDA) provide guidelines on the development and validation of dissolution procedures [96,97]. Most of these guidelines are for solid oral dosage forms like tablets and hard gelatin capsules; however, one cannot extrapolate these methods to SGCs without proper assessment. The choice of dissolution method should be based on the dosage form and the fill characteristics of SGCs. shows the common USP dissolution apparatus used in dissolution testing.<\/p>\n\n\n\n

 <\/h3>\n\n\n\n

Developing a discriminating dissolution test for SGCs requires special considerations and knowledge of gelatin and fill material properties and factors influencing them. Several factors affect the dissolution behavior of SGCs and subsequently affect the development of dissolution procedures. These factors include physical properties of the gelatin shell, physical and chemical properties of the fill material, chemical interaction between the gelatin shell and fill components, and moisture exchange between the shell and the fill material. In particular, moisture exchange can potentially result in brittleness of the gelatin shell, and chemical interactions between the shell and fill could result in gelatin cross-linking.<\/p>\n\n\n\n

Two key considerations in the design and development of dissolution methods are the solubility of the active ingredient and solution stability of the SGCs. To establish a suitable medium, several dissolution media should be evaluated to identify the one that achieves appropriate sink conditions. Sink conditions can be defined as the volume of medium that is at least three times the saturated solubility of the API, with the lowest quantity of designated surfactant. These studies allow optimization and observing the amount of surfactant that is needed to solvate the fill material within a time that is relevant to the dissolution test. It is more reasonable that a dissolution result reflects the properties of the API under the sink conditions; however, a medium that fails to provide sink conditions may be acceptable by the USP if it is appropriately justified. Likewise, when choosing the medium, the effect of additives such as acid and salt concentration, buffer counter-ions and co-solvents, and types of enzymes and their activity must also be evaluated and justified, if used. The solubility improvement of the API depends on various factors, including the nature of the surfactant and the fill material, temperature, pH, and ionic strength. This relationship should be understood for different surfactants and compounds before executing the dissolution experiment.<\/p>\n\n\n\n

Typical media for dissolution studies include: dilute hydrochloric acid (0.1 N), buffers in the physiologic pH range of 1 to 7.5 (i.e., phosphate, acetate, or citrate), simulated gastric or intestinal fluid (with or without enzymes), water, and surfactants such as Tween, Brij 35, Triton, polysorbate 80, cetyl trimethyl ammonium bromide (CTAB), sodium lauryl sulfate (SLS), and bile salts [100]. Some SGC formulations may contain a matrix or API that is not soluble in water or acidic environment and consequently, does not meet sink conditions in aqueous solution. In these instances, surfactants with a justified concentration may be added to the dissolution medium. The choice of surfactant and its concentration in relation to solubility and physical stability of the API is critical and must be optimized, understood, and justified. The addition of surfactant should reflect changes in the formulation and interactions among fill components and may shed light on the in vivo behavior of the SGCs.<\/p>\n\n\n\n

Surfactants play a role in dissolution by replacing water molecules on the particle surface, which reduces interfacial tension between the solution and the surface [101]. Amidon et al. has proposed that the use of media containing surfactants is a suitable method for solubilizing such drugs because various surfactants are present in the GI fluid, e.g., bile salts, lecithin, cholesterol and its esters [102]. They consist of two distinct components, hydrophilic and hydrophobic, and are categorized into four groups according to the charge on the hydrophilic group: anionic (e.g., sodium lauryl sulfate (SLS)), cationic (e.g., cetyl trimethyl ammonium bromide (CTAB), zwitterionic (e.g., alkyl betaine) [101], and non-ionic (e.g., Tween and Triton) [103,104]. Dissolution media containing cationic surfactants are better able to discriminate dissolution rates of acidic fill materials, while anionic surfactants differentiate better for basic fill materials. SLS has been reported to be the most commonly used surfactant in dissolution studies [100]. Solubility and dissolution rate enhancement by the surfactants are a function of surfactant concentration and the size of a micelle, and its stability, all of which can be related to the critical micelle concentration (CMC) [105]. The CMC is defined as the minimum concentration of a surfactant\u2019s monomer at which it aggregates to micelles and is characteristic for each surfactant. A lower CMC value for a given surfactant means the micelles are more stable [106]. Furthermore, the knowledge of the molecular structure of the surfactant can provide information on the size of the micelles.<\/p>\n\n\n\n

It is important to note that the addition of surfactant to dissolution media can sometimes cause a decrease in the dissolution rates of some drug products, and in some instances can also distort drug peaks during high-performance liquid chromatography (HPLC) analysis ( ). In a previous study [63], it was found that an immediate-release SGC, containing a poorly soluble drug, loratadine, showed peaks distortion in the presence of SLS. A similar observation of a decrease in the dissolution of gelatin capsules with SLS at lower pH has also been reported by other research groups [107,108].<\/p>\n\n\n\n

The development of simulated fluids for dissolution testing requires understanding of the physiological conditions of the GIT. It is important to note that the GIT is complex and has a regional dependence drug absorption [109]. Several physiological factors that can affect the dissolution process in vivo include: surfactants in gastric juice and bile, viscosity of the GI contents, GI mobility patterns, GI secretions, pH, buffer capacity, and co-administration of fluids or food [110]. Vertzoni et al. [111] developed a fasted-state simulated gastric fluid (FaSSGF) containing sodium taurocholate, lecithin, and pepsin at pH of 6.5 in order to assess its importance for the in vivo dissolution of lipophilic compounds. The authors concluded that simulation of the gastric content was essential in order to assess the absorption profile of lipophilic weak bases. An overview of the composition of the common in vitro bio-relevant dissolution media is provided by Klein [112] and Galia et al. [113]. Likewise, simulated dissolution media must take into account the developmental changes in gastrointestinal fluid composition because these can result in variations in luminal drug solubility between children and adults. Therefore, evaluating age-specific changes in GI fluid parameters (i.e., pepsin concentration, bile acids, luminal viscosity, pH, osmolality, etc.) is very important in order to define the composition of bio-relevant dissolution media in pediatrics [114]. Furthermore, aged population with medical conditions such as hypochlorhydria and achlorhydria have elevated gastric pH [115]. Therefore, simulated dissolution media in this population may need to be adjusted to reflect this increased pH.<\/p>\n\n\n\n

The selection of dissolution apparatus is another critical step in the dissolution evaluation of SGCs, as the mixing efficiency of fill material contents with media is very much influenced by the agitation hydrodynamics, particularly to variables such as paddle rotation speed. The two commonly used methods for evaluating the dissolution properties of SGCs are the paddle and basket methods.<\/p>\n\n\n\n

A basket apparatus has the advantage of enclosing SGCs. This method may be selected if SGCs are filled with a material that has a specific gravity less than that of water, where baskets prevent the SGC and its components from floating in the medium. One common problem observed using the basket is that during the dissolution experiment, the soft gel shell may disintegrate into a soft and sticky mass that can clog the basket\u2019s mesh, generating high variability in the results. Additionally, if the fill material is hydrophobic, i.e., an oil-based fill, dispersion into fine droplets that can pass through the basket\u2019s mesh may not take place, giving rise to a delay in dissolution that is not representative of the true properties of the SGCs. To mitigate this problem, an alternative would be using a basket with larger pores, i.e., 20 or 10 mesh sizes [116]. Pillay and Fassihi used a rotating basket method to evaluate the dissolution of lipid-based SGCs of nifedipine. Their data showed that, after six hours of dissolution test, most of the viscous oily fill formulation was still entangled within the baskets and this led to the dissolution failure [55]. This was attributed to using the standard dissolution basket with pores size of 40 mesh, combined with inappropriate hydrodynamic conditions within the basket. However, when the dissolution test was repeated using a re-designed dissolution apparatus, in this case, nifedipine SGCs showed the best dissolution profiles.<\/p>\n\n\n\n

The paddle method constitutes about 70% of the dissolution methods used by FDA-approved commercial drug products [100]. This method does not use a mesh basket to contain the capsules, and so a common initial problem observed in this method is the floating of the SGCs to the surface of the dissolution medium once it breaks. In these instances, wire coils, also known as sinkers, can be used to enclose the soft gels and hold them on the bottom of the vessel [117]. This allows the fill to be better exposed to the medium (upon shell rupture) and helps to prevent the capsule from sticking to the vessel walls. The shape and size of the sinker should be selected carefully as it can impact the dissolution process, especially in cases where SGCs swell when they encounter the dissolution medium. In previous study, it was shown that the dissolution rate obtained using the paddle method was faster, highly variable at lower time points than those obtained using the basket. In contrast, the data collected using the basket dissolution apparatus showed that the method was more selective and had less variation in terms of API release profile [63]. shows examples of SGCs that are commercially available and their dissolution methods. Other research groups have evaluated the feasibility of using the USP III in evaluating the dissolution of SGCs. Monterroza and Ponce De Le\u00f3n [118] developed a discriminating dissolution method of SGCs containing an oily suspension of micronized progesterone. They compared the dissolution profiles generated using USP 1, 2, and 3. After preliminary tests, USP 1 and USP 2 methods did not reach the target of releasing more than 85% of the API in less than 90 min. However, USP 3 showed promising prospect of releasing more than 85% of the API in less than 90 min in the presence of 250 mL of 4% of SLS in pH 6.8 phosphate.<\/p>\n\n\n\n

 <\/h3>\n\n\n\n

In some cases, such as coated SGCs, a two-step or two-tier dissolution technique must be developed [120,121,122]. The purpose of this method is to assess the integrity of the coating in the acidic conditions of the stomach and measure the drug release in lower parts of the GIT, which have near-neutral pH conditions. Manually performing the two-step dissolution test is labor-intensive and requires well-trained analysts. For example, it requires pre-heating the second medium solution, adjusting the medium by adding the second part of the solution as well as adjusting and confirming pH for six vessels within 5 min. Typically, there are two approaches towards medium modification known as medium-addition or medium-exchange. For example, both approaches may start with an acidic step, such as 0.1 N hydrochloric acid, for a certain period, followed with a buffer step, such as phosphate buffer at pH 6.8. The specific time is chosen as needed for the individual drug product. While using either approach, the pH adjustment must be accomplished in a controlled and reproducible manner via pre-heated media. The operation of adding and adjusting the pH must be done within 5 min [123]. Zhao and co-workers described a two-step dissolution method using medium addition and paddle apparatus, in which the surfactant Tween 80 was included in the media to enhance the solubility of the API in the first stage [124]. The developed dissolution method was able to discriminate against the changes in composition, manufacturing process, and stability of the drug product. When developing a two-step dissolution procedure, several factors must be carefully examined to establish a suitable medium. The most critical step is to carefully evaluate different media to identify the one that achieves the sink conditions. The fill material may have a pH-dependent solubility, so an evaluation of the solubility of the compound in both the acidic and neutral media must be made. For instance, 0.1 N HCl and 50 mM pH 6.8 phosphate buffers are commonly used media.<\/p>\n\n\n\n

The medium-addition technique, which is used for a two-step dissolution for enteric-coated capsules or two-tier dissolution testing, uses paddle or basket apparatus. This approach requires the addition of a relatively small amount of medium to each vessel in a short time. Generally, the common dissolution volumes used are in the range of 500 to 1000 mL, with 900 mL being the most commonly used in the FDA-approved drug products [100]. However, the dissolution volumes should be defined by the sink conditions. To develop a robust two-step dissolution method which can be transferred to quality control, a medium addition method is preferred where a volume of, e.g., 200 mL, can be added to 700 mL initial volume to adjust pH, and then add the surfactant, or enzyme, depending on the soft gelatin capsule drug product [124]. Furthermore, an accurate volume of the medium must be added to ensure that a volumetric error does not occur. Likewise, media addition must consider the final desired pH of the final volume. This technique is less invasive for the SGCs and is easier to conduct in a short time when running multiple batches. This approach is also less labor-intensive and allows for higher sampling throughput during the experiment run. For use in enteric-coated drug products, the API should be soluble up to the specification level in the medium of the first step to be able to detect a failure in the coating. For example, if the specification level for the first step is not more than 10% released, then this medium must be able to dissolve at least 10% of the active ingredient in the soft-gelatin capsule drug product. If the fill material is not soluble in the first-step medium, a surfactant may be added to solubilize at least 10% of the API in the fill material [124]. For use in two-tier dissolution, the fill material would require the surfactant to be present to meet solubility requirements, but also needs the enzyme to overcome the cross-linking.<\/p>\n\n\n\n

For the medium-exchange approach used for enteric-coated capsules, the acid medium is drained after the first step, and a full amount of pH 6.8 buffer that has been equilibrated at similar conditions is added to the same vessel for the buffer stage. The dosage form should be undisturbed during the medium change. The complete medium replacement method resembles the medium-addition approach in that the capsules are first introduced to an acidic medium. At the end of the first step, a sample for analysis is taken, and then the dosage form is removed from the acidic conditions. Removing technique of dosage form depends on the type of dissolution apparatus. The dosage forms may be manually moved from one vessel to another. Alternatively, the entire vessel containing the acid could be removed and replaced with another vessel containing the buffer, and the dosage form is transferred to the new vessel. The quality of the SGCs dosage form is ensured by meeting the USP acceptance criteria for the acid stage, i.e., less than 10% of the API is released from the drug product during the first step of the developed dissolution technique, and therefore, the coating is considered to have passed the acid-step test. If each unit release is not less than Q + 5% for the buffer stage, then the soft gel dosage form has passed the second step of dissolution [125]. Q represents the amount of an active ingredient dissolved in the dissolution medium, expressed as a percentage of the labelled content. To overcome the challenges of manual manipulations of adding the buffer solutions and adjusting the pH during the two-step dissolution testing, other research groups have developed semi-automated dissolution systems for these measurements [125]. The media exchange technique is challenging for SGCs, especially if the capsules have softened due to the liquid exposure, soaking alone will cause some softening but may not cause the rupture of the capsule. Therefore, the transfer of the capsule or media removal without disturbing the shell may be difficult due to mechanical stress.<\/p>\n\n\n\n

The European Medicines Agency (EMA) has developed its own guidance on in vitro dissolution tests for immediate-release drug products [126]. In dissolution guidance, EMA describes specifications for the quantity of active substance dissolved in a specified time, which is expressed as a percentage of API on the product label. The goal of the guidance is to set specifications to ensure batch-to-batch consistency and highlight possible problems with in vivo bioavailability. The guidance for solid immediate-release (IR) drug products from the European Pharmacopoeia (Ph. Eur. 5.17.1) has some differences compared with the FDA specifications. From a pharmaceutical perspective, the European Pharmacopoeia (Ph. Eur.) states that IR formulations should normally achieve in vitro dissolution of at least 80% of the drug substance within not more than 45 min. However, based on the USP guidance, in general, 85% or more of the drug substance should be released within 30 to 45 min.<\/p>\n\n\n\n

Dissolution methods for SGCs must also consider the aspect of age-related gelatin cross-linking influencing the dissolution performance. The USP permits the use of a two-tier assessment of hard and SGCs when evidence of cross-linking is present. Evidence of cross-linking usually occurs based on visual observations during the performance of the dissolution testing. This is based on the fact that the USP general chapters on dissolution as well as disintegration and dissolution of dietary supplements , allow the addition of various enzymes based on pH of the dissolution medium when hard or SGCs and gelatin-coated tablets do not conform to the dissolution or to resolve potential cross-linking issues specifications [127]. Cross-linking evidence can come in the form of poorly dissolving gelatin shell or pellicle formation, which appears as a sac surrounding and containing the fill material after the shell is dissolved (see Section 8). To overcome cross-linking, the two-tier dissolution test would involve the addition of proteolytic enzymes such as pepsin, papain, bromelain, or pancreatin to the dissolution media and repeating the dissolution [128]. These enzymes effectively digest the peptide bonds between the amino acids making up the gelatin strands in the shell. The use of enzymes for dissolution must be done with care, as the enzymes require significant mechanical mixing to get into solution, are minimally stable in solution, and can be impacted by other components of the media, such as surfactants. If a protein denaturing surfactant [129] is used in the media, a two-step tier 2 method must be performed. The first step involves the dissolution of the capsule shell using media containing an enzyme and no surfactant as a pre-treatment step. After the capsule shell is dissolved, media containing surfactant is added to complete the dissolution and solubilization of the fill and active pharmaceutical ingredient. It was observed that using the digestive enzyme while conducting the dissolution study and afterward using the surfactant showed a better effect in the two-tier method [130].<\/p>\n\n\n\n

Another important aspect that is worth discussing regarding dissolution of SGCs is the concept of an in vitro\u2013in vivo correlation (IVIVC). This is normally used to establish a relationship between an in vivo response (e.g., amount of drug absorbed) and an in vitro physicochemical property of a dosage form. The main objective of this concept is to make sure that the in vitro properties of two or more batches of the same drug product are performing similarly under in vivo conditions. Hence, this relationship is essentially important in guiding drug development and drug approval processes that are designed to mimic the in vivo drug release. There have been various studies on IVIVC of SGCs and some have shown good correlations. Meyer et al. [53] assessed whether the changes in the in vitro dissolution of hard and soft gelatin acetaminophen capsules, as a result of gelatin cross-linking, are predictive of changes in the bioavailability of the capsules under in vivo conditions. Their data showed that the in vitro rate of dissolution of hard and SGCs decreased due to cross-linking. On the other hand, the bioequivalence studies showed that both hard and SGCs, which failed to meet the USP dissolution specification in water, but complied when tested in SGF containing pepsin, were bioequivalent to the unstressed control capsules. Based on the plasma concentration parameters, the capsules that were cross-linked to the greatest extent were not bioequivalent with the unstressed control capsules. In another study, Nishimura et al. [131] attempted to predict the human plasma drug concentrations of SGCs containing a poorly soluble drug, arundic acid. SGCs were stored at short- and long-term conditions, i.e., 15 \u00b0C for 3 months and 25 \u00b0C (60% relative humidity (RH)) for 30 months, respectively. The authors showed that the in vitro dissolution data obtained with the dissolution medium containing surfactant (i.e., 2% SLS, pH 6.8) were more effective in predicting the drug plasma concentrations following oral administrations of the SGCs under both storage conditions. Likewise, Rossi et al. [132] developed and validated a dissolution test for ritonavir SGCs based on human in vivo pharmacokinetic data. The authors used a USP II method with 900 mL of dissolution medium containing water with 0.3%, 0.5%, 0.7%, or 1% (w\/v) of SLS at rotation speed of 25 rpm. Their data showed strong level A correlation between the percent of the drug dissolved versus percent absorbed. Significant in vitro\u2013in vivo correlation was achieved using dissolution medium containing water with 0.7% SLS. In another similar study, Donato et al. [133] reported similar results on the development and validation of a dissolution test for lopinavir, a poorly water-soluble drug, in soft gel capsules, based on in vivo data. In this work, a new formulation of lopinavir was developed and its dissolution tests validated using in vivo data. All formulations were evaluated for in vitro dissolution containing 2.3% SLS at pH 6.0 and USP 1 at 25 rpm. At these conditions, the authors showed strong level A correlations for the fraction dissolved versus fraction absorbed.<\/p>\n\n\n\n

Group has got lots of patents in Zselatin kapszula kem\u00e9nys\u00e9gm\u00e9r\u0151<\/a>,Automatikus kapszula kem\u00e9nys\u00e9gm\u00e9r\u0151<\/a>,Orvosi eszk\u00f6z tesztel\u0151<\/a>,Orvosi term\u00e9kek vizsg\u00e1lati eszk\u00f6zei Gy\u00e1rt\u00f3<\/a>,Motoriz\u00e1lt kupak nyomat\u00e9km\u00e9r\u0151<\/a>,Kont\u00e9ner tesztel\u0151<\/a>,Sz\u00f6vetvastags\u00e1g tesztel\u0151<\/a>,Digit\u00e1lis teszt\u00e1llv\u00e1ny<\/a>,F\u00fcgg\u0151leges szak\u00edt\u00f3pr\u00f3ba<\/a>, and support engineer construction and timely after-sales service, the company has established a lead position in the industry.<\/p>\n\n\n\n

Ha tov\u00e1bbi inform\u00e1ci\u00f3kat szeretne err\u0151l a term\u00e9kr\u0151l, k\u00e9rj\u00fck, forduljon hozz\u00e1nk bizalommal. Aj\u00e1nljuk \u00d6nnek m\u00e1s n\u00e9pszer\u0171 term\u00e9keket: kapszula kem\u00e9nys\u00e9gm\u00e9r\u0151<\/a>
<\/p>","protected":false},"excerpt":{"rendered":"

Mi az a l\u00e1gykapszula kem\u00e9nys\u00e9gm\u00e9r\u0151? A l\u00e1gyzselatin kapszul\u00e1kat csomagol\u00e1s el\u0151tt rugalmass\u00e1gi vizsg\u00e1latnak kell al\u00e1vetni. Itt van sz\u00fcks\u00e9g a tesztel\u0151re, \u00e9s nem egy k\u00f6z\u00f6ns\u00e9ges tesztel\u0151re. A kapszul\u00e1k gy\u00e1rt\u00f3inak sz\u00fcks\u00e9g\u00fck van egy megb\u00edzhat\u00f3 l\u00e1gyzsel\u00e9s kapszula kem\u00e9nys\u00e9gtesztel\u0151re, hogy megbizonyosodjanak arr\u00f3l, hogy term\u00e9keik megfeleltek a meghat\u00e1rozott ipari szabv\u00e1nymin\u0151s\u00e9gnek, miel\u0151tt a term\u00e9keket a fogyaszt\u00f3nak [...].<\/p>","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1022","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"_links":{"self":[{"href":"https:\/\/test.geo-tester.com\/hu\/wp-json\/wp\/v2\/posts\/1022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/test.geo-tester.com\/hu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/test.geo-tester.com\/hu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/test.geo-tester.com\/hu\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/test.geo-tester.com\/hu\/wp-json\/wp\/v2\/comments?post=1022"}],"version-history":[{"count":0,"href":"https:\/\/test.geo-tester.com\/hu\/wp-json\/wp\/v2\/posts\/1022\/revisions"}],"wp:attachment":[{"href":"https:\/\/test.geo-tester.com\/hu\/wp-json\/wp\/v2\/media?parent=1022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/test.geo-tester.com\/hu\/wp-json\/wp\/v2\/categories?post=1022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/test.geo-tester.com\/hu\/wp-json\/wp\/v2\/tags?post=1022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}